Granted Patent B2

US 12,466,818 · App. 17/294,779 · Granted Nov 11, 2025

Inventors: John Kincaid (Boston, MA); Matthew Duncton (Boston, MA)

Assignee: NFlection Therapeutics, Inc.

C07D409/06A61P17/00C07D333/38C07D333/68C07D409/12C07D413/06

Abstract

Claims (27)

1 . A compound of Formula (Ic) or (Ie-1):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is —N(OR 5b )R 5a ;

R 2 is halo;

R 2a is halo;

R 3a is C 1 -C 6 alkyl;

R 5b is C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl, C 1 -C 6 hydroxyalkyl, or amino-C 1 -C 6 alkyl;

R 5a is hydrogen;

R 6 is C 1 -C 6 alkyl; and

each R 9 is independently C 1 -C 6 alkyl.

2 . The compound of claim 1 , having formula Ic:

3 . The compound of claim 1 , wherein R 6 is methyl, ethyl, propyl, or butyl.

4 . The compound of claim 1 , wherein R 3a is methyl.

5 . The compound of claim 1 , having formula (Ie-1):

6 . The compound of claim 5 , wherein R 9 is absent.

7 . The compound of claim 1 , wherein R 2 is iodo.

8 . The compound of claim 1 , wherein R 2a is fluoro.

9 . The compound of claim 1 , wherein R 5b is C 3 -C 8 cycloalkyl-C 1 -C 6 alkyl or amino-C 1 -C 6 alkyl.

10 . The compound of claim 1 , wherein R 5b is C 1 -C 6 hydroxyalkyl.

11 . The compound of claim 1 , selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

12 . A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

13 . The compound of claim 1 , having the structure:

14 . The compound of claim 1 , having the structure:

15 . A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier.

16 . A pharmaceutical composition comprising the compound of claim 14 and a pharmaceutically acceptable carrier.

Assignments (2)

Continuity (2)

References Cited (126)